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Edited by Richard MaraisAbstract Ca2+-sensitization of smooth muscle occurs through
inhibition of myosin light chain phosphatase (MLCP) leading to
an increase in the MLCK:MLCP activity ratio. MLCP is
inhibited through phosphorylation of its regulatory subunit
(MYPT-1) following activation of the RhoA/Rho kinase
(ROK) pathway or through phosphorylation of the PP1c
inhibitory protein, CPI-17, by PKC d or ROK. Here, we
explore the crosstalk between these two modes of MLCP
inhibition in a smooth muscle of a natural CPI-17 knockout,
chicken amnion. GTPcS elicited Ca2+-sensitized force which was
relaxed by GDI or Y-27632, however, U46619, carbachol and
phorbol ester failed to induce Ca2+-sensitized force, but were
rescued by recombinant CPI-17, and were sensitive to Y-27632
inhibition. In the presence, but not absence, of CPI-17, U46619
also signiﬁcantly increased GTP RhoA. There was no aﬀect on
MYPT-1 phosphorylation at T695, however, T850 phosphory-
lation increased in response to GTPcS stimulation. Together,
these data suggest a role for CPI-17 upstream of RhoA
activation possibly through activation of another PP1 family
member targeted by CPI-17.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Ca2þ-sensitization of smooth muscle myosin II, a highly
relevant physiological process, reﬂects the ratio of myosin light
chain kinase (MLCK) and myosin light chain phosphatase
(MLCP) activities that determine the level of myosin light
chain phosphorylation (MLC20) and force [1–3]. Agonists in-
duce Ca2þ-sensitization by inhibition of MLCP through acti-
vation of G-protein coupled receptors (GPCRs) which activate
guanine nucleotide exchange factors (GEFs) that catalyze the
exchange of GDP for GTP on RhoA, its translocation to the
cell membrane and activation of Rho kinase (ROK) [4,5].
Evidence, in vitro [6,7] and in vivo [8], suggests that inhibitory
phosphorylation of MYPT-1 may occur at several sites. The* Corresponding author. Fax: +1-434-982-1616.
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doi:10.1016/j.febslet.2004.10.072relevant sites in smooth muscle tissues are unclear. The iden-
tiﬁed ROK phosphorylation sites in chicken MYPT-1 (133
kDa) are threonine 695 (T695) and serine 849 (S849) corre-
sponding, respectively, to T696 and S852 in the human se-
quence. Also, it has been demonstrated in vitro that the
phosphorylation of T850 by ROK leads to dissociation of the
phosphatase from myosin [7].
MLCP activity can be modulated by other mediators such as
CPI-17, a 17-kDa peptide [9], where phosphorylation at Thr-
38 inhibits PP1c, the catalytic subunit of MYPT-1. Recently, it
has been demonstrated that CPI-17 is a substrate for a number
of kinases including PKC [10], Zip-like kinase [11], integrin-
linked kinase [12], the Rho eﬀector PKN [13] as well as ROK
[14]. ROK phosphorylation of CPI-17 in vitro is inhibited by
the ROK inhibitor, Y-27632 [15,10], suggesting a possible link
between RhoA and CPI-17 in the Ca2þ-sensitization pathway.
MLCP activity can also be increased through PKG-mediated
inhibition of RhoA [16] or possibly through interaction be-
tween the leucine zipper motifs of PKGIa and MYPT-1 [17].
In this study, we have taken advantage of a special prepara-
tion, chicken amnion (ASM), which does not express CPI-17,
to examine the interdependence of the RhoA/ROK and the
CPI-17 signaling pathways in the regulation of Ca2þ- sensiti-
zation. As the signaling between GPCRs and RhoA activation
is poorly understood in smooth muscle, we have also identiﬁed
the expression of two RhoGEFs, LARG and PDZ-RhoGEF
in native smooth muscle providing evidence of a means of
activation of RhoA in Ca2þ-sensitization.2. Materials and methods
2.1. Materials and chemicals
a-Toxin was puriﬁed from Staphylococcus aureus. A23187, U-
46619 (Calbiochem, La Jolla, CA), Y-27632 (Mitsubishi Pharma
Corp., Yokohama, Japan), anti-Rho A (sc179), anti-Gaq=11 (sc392),
anti-Ga12 (sc409), and anti-Ga13 (sc410) antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA), anti-chicken ROK (generous gift
from Dr. L. Lim, Singapore), anti-MYPT-1 (MMS-458R) antibody
(Covance, Princeton, NJ), anti-pS854 (phospho-serine 849 in chick-
en) MYPT-1 antibody (generous gift from Dr. K. Kaibuchi, Nagoya
University, Japan), anti-pT695 MYPT-1 and anti-pT850 MYPT-1
antibodies (Upstate Biotechnology, Lake Placid, NY). Anti-PP1d
and anti-CPI-17 were prepared as described previously [18]. CPI-17
antibody raised against pig CPI-17 has been shown to react with
pigeon CPI-17 [19]. Recombinant RhoA GDI was prepared asation of European Biochemical Societies.
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bodies were generously provided by Dr. S. Gutkind, NIH. Eggs
were purchased from Truslow Farms Inc. (Chestertown, MD) and
maintained in a Turn-X incubator (Lyon Electric Co., Chula Vista,
CA).
2.2. Isometric tension measurement
Chicken amnion sheets (approximately 3 3 mm) from 8 to 14 day
eggs were dissected and attached to a ﬁxed hook and force transducer
(AE 801; AME, Horten, Norway) to record isometric tension, at room
temperature, in HEPES-buﬀered Krebs solution (according to pub-
lished protocol [5]).
2.3. Ca2þ-sensitization and protein phosphorylation
Amnion sheets were permeabilized in relaxing solution (G1) (con-
taining 1 mM EGTA) with Staphylococcus aureus a-toxin (0.1 mg/ml)
or b-escin (75 lM) for 30 min at 22 C and subsequent incubation in
the presence of A23187 (10 lM) for 20 min. At the appropriate time
point, muscle sheets were rapidly frozen in liquid nitrogen, transferred
to pre-cooled 10% TCA/acetone, and processed by freeze substitution
as reported previously [21] and centrifuged. Samples in Laemmli
sample buﬀer were separated by SDS–PAGE (7.5% polyacrylamide for
MYPT-1 and 15% for MLC20) and transferred to PVDF membranes
before Western blotting with monoclonal anti-MYPT-1 (1:10 000) or
polyclonal anti-phospho-MYPT-1 antibodies (anti-T695, 1:2000; anti-
S854, 1:50; and anti-T850, 1:1000).
2.4. RhoA translocation
In order to separate cytosolic and particulate fractions, two amnion
sheets from stimulated and control (approximately 3 3 mm) were
used per sample. These were prepared for SDS–PAGE analysis ac-
cording to the method previously described [5].
2.5. mDia and Rhotekin assay for GTP-RhoA
Active RhoA was aﬃnity precipitated using the Rho binding do-
main (RBD) of mDia or Rhotekin. pGEX-4T-1 mouse mDia or
Rhotekin RBD was introduced into Escherichia coli, and the GST
fusion protein was expressed, conjugated to glutathione beads, and
puriﬁed. Following a-toxin or b-escin permeabilization and treatment
with the Ca2þ ionophore A23187 for 10 min. the samples were
transferred to submaximal Ca2þ (pCa 6.5) and treated with various
agents as indicated for 10 min. Tissues were ﬂash frozen in liquid
nitrogen and stored at )80 C, then homogenized in a buﬀer con-
taining: 50 mM Tris–HCl (pH 7.5), 100 mM NaCl, 1 mM EGTA, 5
mM MgCl2, 10% glycerol, 50 mM NaF, 1 mM Na3VO4, 1 mM di-
thiothreitol (DTT), 0.5% Nonidet P-40, and a protease inhibitor
mixture, centrifuged and supernatants incubated with 30 lg of the
GST-RBD fusion protein conjugated with glutathione beads for 45
min at 4 C. Beads were pelleted, washed and supernatants saved.
DTT and Laemmli sample buﬀer were added to the samples, fol-
lowed by boiling and separation of the beads by centrifugation and
electrophoresis on an SDS–PAGE gel. RhoA was detected by Wes-
tern blot analysis using a polyclonal antibody against RhoA (1:1000).
Bound RhoA was normalized to the RhoA in the whole extract of a
given sample.Table 1
Agonist-induced contractile responses in intact versus permeabilized chicken
Agonist Concentration Response
Intact
Carbachol 10–100 lM +++
5-HT 10 lM ++
Phenylephrine 100 lM –
U-46619 0.3–1 lM –
Oxytocin 600 nM –
PDBu 1 lM r
Arachidonic acid 300 lM r
GTPcS 10–300 lM –
AlF4 10 lM –
‘+’ denotes contraction, ‘–’ denotes no response, ‘r’ denotes relaxation and2.6. Western blots for ROK, Ga subunits, PKC isoforms, and RhoGEFs
Supernatants from whole tissue homogenate were solubilized in 1
Laemmli sample buﬀer and clariﬁed (800 g, 10 min) before SDS–
PAGE. Immunoblotting was carried out as previously described [5].
The primary antibody dilutions were 1:1000 for chicken polyclonal
anti-ROK antibody; 1:5000 for Ga antibodies; 1:200 or 1:1000 (as
indicated) for PDZ-RhoGEF and LARG antibodies.
2.7. Primary cultures of chicken amnion smooth muscle
Sheets of smooth muscle were dissected from chicken eggs and
maintained in culture in DMEM/F12 medium + 10% FBS at 37 C.
Explanted primary cultures were treated as speciﬁed before terminat-
ing the reaction at the appropriate time point following exchange of
the culture media for lysis buﬀer containing: 1% SDS, 1 mM EDTA, 1
mM Na3VO4, 0.4 mM AEBSF, and 50 mM Tris–HCl, pH 7.4. Iden-
tiﬁcation of smooth muscle cells was conﬁrmed by immunostaining
using an anti-smooth muscle-a-actin antibody (1:20 000).3. Results and discussion
3.1. Agonist-induced responses of intact amnion smooth muscle
A wide variety of agonists leading to contractile responses in
smooth muscle mediated through increases in cytosolic [Ca2þ]
and/or Ca2þ-sensitization were explored in intact amnion
(Table 1). The muscarinic agonist, carbachol (10 lM), and 5-
hydroxytryptamine (5-HT) (10 lM) elicited fast, phasic con-
tractions in intact chicken amnion, whereas the a-adrenergic
agonist phenylephrine (100 lM), the thromboxane analog U-
44619, a strong Ca2þ sensitizer, and oxytocin (600 nM) were
without eﬀect, indicating selectivity for some GPCR agonists
in chicken amnion. PDBu (1 lM), a phorbol ester, consistently
caused a small relaxation in intact ASM along with the PKC
activator arachidonic acid (300 lM).
3.2. Ca2þ-sensitization of a-toxin permeabilized amnion smooth
muscle
Surprisingly, despite responses of intact amnion to carba-
chol and 5-HT, these agonists did not induce Ca2þ-sensitiza-
tion in the a-toxin permeabilized amnion consistent with
responses in the intact amnion being due to Ca2þ release and
inﬂux. In contrast, GTPcS (10 lM), a non-hydrolyzable form
of GTP, elicited a robust Ca2þ-sensitization (Fig. 1A, a) as did
AlF4 (10 lM AlCl3/3 mM NaF), a non-speciﬁc activator of
heterotrimeric G-proteins and RhoA (reviewed in [3]) (Table 1;
Fig. 1A, c). The amplitude of Ca2þ-sensitization by GTPcS
was 29.4 2.4% (n ¼ 11) of the maximum tension (pCa 4.5)












‘nt’ denotes not tested.
Fig. 1. Representative tension traces illustrating Ca2þ-sensitization in a-toxin permeabilized chicken amnion smooth muscle strips. (A) Ca2þ-sen-
sitization can be induced by GTPcS (a) and AlF4 (c) and inhibited by ROK inhibitor, Y-27632 (10 lM) (a, c) or 8-bromo-cGMP (5 lM) (b). GTPcS-
induced sensitization can also be reversed by GDI (d). Data summary (e and f). GTPcS induced increase in RhoA-GTP assayed using the Rho
binding domain of mDia (B) and RhoA translocation from the cytosol, C, to the particulate, P, fraction (C).
A.S. Stevenson et al. / FEBS Letters 578 (2004) 73–79 75and reversibly relaxed the GTPcS-induced sensitization
(Fig. 1A, f). AlF4 caused a signiﬁcant increase in Ca
2þ-sensi-
tization (20.2 4.3% of maximum at pCa 4.5; n ¼ 10)
(Fig. 1A, e) and was inhibited by Y-27632 (81.5 19% of
AlF4 -induced sensitization) (Fig. 1A, f). Thus, it can be con-
cluded from these data that the signaling steps downstream of
activated RhoA are intact in the amnion, but it is not clearwhether coupling between heterotrimeric G protein activation
andRhoA activation leading to Ca2þ sensitization is functional;
as AlF4 may also activate RhoA directly [22] and GTPcS
activates heterotrimeric and monomeric GTPases. GTPcS-
induced contraction of ASM was attenuated by addition of 8-
br-cGMP, a non-hydrolyzable analog of cGMP (Fig. 1A, b and
f). We have shown previously that 8-bromo-cGMP can induce
76 A.S. Stevenson et al. / FEBS Letters 578 (2004) 73–79Ca2þ-desensitization by stimulation of cyclic GMP-dependent
kinase thus increasing MLCP activity, decreasing RLC20
phosphorylation and counteracting the inhibition of GTPcS
stimulated phosphatase activity [23]. Thus, the mechanisms
responsible for inhibition and activation of MLCP appear
normal in ASM.
To further verify that GTPcS-induced Ca2þ sensitization in
ASM, as in other smooth muscles, was via a pathway that
involves RhoA and ROK, we investigated whether addition of
the guanine exchange dissociation inhibitor, recombinant
Rho GDI, could reduce GTPcS-induced contraction in ASM.
As expected from data in rabbit smooth muscles [24],
Rho GDI completely reversed the GTPcS-induced sensitiza-
tion (Fig. 1A, d and f). GTPcS caused an increase in activated
RhoA (GTP RhoA) detected in a pulldown assay using the
Rho-binding domain of mDia, a RhoA eﬀector [25], as a GST
fusion protein (Fig. 1B). We further determined whether ac-
tivation of RhoA is also accompanied, as in other cells, by its
translocation to the plasma membrane. GTPcS caused Ca2þ-
independent translocation of RhoA from the cytosol to the
particulate fraction in permeabilized ASM (Fig. 1C). These
results indicate that the downstream signaling pathways of
activated RhoA and ROK are functional in ASM. Thus, the
deﬁciency of agonist-induced sensitization is most likely due to
lack of upstream coupling, with the ‘‘uncoupling’’ occurring
upstream of RhoA activation.
3.3. Expression of known players in the Ca2þ sensitization
pathway
Western blot analysis of Gaq=11 revealed no qualitative dif-
ferences in its expression relative to total protein between
homogenates of ASM and rabbit portal vein, which is known
to express Gaq=11 (Fig. 2A). Ga12 and Ga13 were also detectable
in ASM preparations, with Ga13 showing higher expression
(Fig. 2A). Expression of ROK was also veriﬁed by Western
blot analysis in ASM, using a polyclonal antibody that wasFig. 2. Expression of proteins known to participate in Ca2þ-sensitization in sm
of 40 lg total protein per lane. (B) ROKa is expressed in chicken amnion to s
amnion represent both Ca2þ-dependent (b1) and Ca2þ-independent (f and d)
PDZ-RhoGEF in chicken amnion; right, expression of PDZ-RhoGEF in var
aorta; d: abdominal aorta; e: bladder; f: ileum; g: femoral artery; and h: rabspeciﬁc to the chicken sequence for ROKa, but that also cross-
reacted with rabbit ileum (Fig. 2B). CPI-17 was not detectable
in ASM but was present in the positive control, rabbit ileum,
consistent with the lack of detection of CPI-17 mRNA in the
chicken using RT-PCR [19]. It was also shown that the CPI-17
antibody reacts well with CPI-17 in another avian species, the
pigeon, but shows no detectable levels of expression in chicken
gizzard smooth muscle [19]. Analysis of the PKC isoforms
showed expression of a conventional (Ca2þ-dependent) iso-
form of PKC, PKC b1, and two non-conventional (Ca2þ-in-
dependent) isoforms, PKC f and PKC d (Fig. 2C). A possible
mechanism that could account for the lack of response in ASM
to agonist stimulation could be the lack of a functional GEF
for RhoA [3]. Two known RhoGEFs, PDZ-RhoGEF and
LARG, were detected in amnion lysates, as well as in a smooth
muscle tissue screen, by immunoblotting (Fig. 2D). Thus, the
presence of PDZ-RhoGEF and LARG plus the mDia assay
demonstrating nucleotide exchange suggests that the GEF
necessary for functional RhoA is present in amnion.
3.4. Regulation of myosin light chain phosphatase (MLCP) in
chicken amnion
To elucidate the mechanism by which GTPcS-induced Ca2þ-
sensitization occurred in ASM; we focused on the inhibition of
myosin light chain phosphatase (MLCP). GTPcS caused a
signiﬁcant increase in MLC20 phosphorylation at constant
[Ca2þ] in chicken amnion (data not shown) as in other cells
including smooth muscle [2,3,5] or non-muscle myosin II [2],
consistent with inhibition of MLCP activity leading to Ca2þ-
sensitization. A regulatory subunit, MYPT-1, has been shown
to contain a number of phosphorylation sites for ROK in-
cluding T695, S849 and T850 (chicken sequence) [6,7,26] and
(at least in vitro) by a variety of other kinases, yet the phos-
phorylation relevant sites are unclear. In tension-monitored
amnion preparations, MYPT-1 phosphorylation at T695, S849
and T850 was determined. Surprisingly, there was no detectableooth muscle. (A) Western blot for heterotrimeric G protein expression
imilar levels as in rabbit ileum. (C) PKC isoforms expressed in chicken
isoforms. (D) Left, Western blot showing the expression of LARG and
ious smooth muscle beds (a: portal vein; b: cerebral artery; c: thoracic
bit ileum).
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presence of GTPcSY-27632, compared to pCa 6.5 alone
(Fig. 3A), despite large diﬀerences in their relative amplitudes
of tension (Fig. 1A). Moreover, there was a signiﬁcant increase
in T850 phosphorylation following stimulation with GTPcS
(43.8 19% of control; n ¼ 4), which was inhibited by Y-27632
by 52.9 11.6% (n ¼ 4) of the GTPcS-induced increase in
phosphorylation (Fig. 3A) and by 8-bromo-cGMP (10 lM
(Fig. 3B) with a corresponding decrease by 108 11.4% in the
GTPcS-induced sensitization (Fig. 1A, b). CPI-17, the inhibitor
of the catalytic subunit of the phosphatase, is not expressed in
any chicken tissues, including gizzard and amnion (Fig. 3B).
Therefore, it appears that phosphorylation of T850 in smooth
muscle tissue is the relevant site for inhibition of MLCP, yet
there are caveats to this conclusion. Recently, it has been shown
that phosphorylation of T696 (human sequence) is inhibited by
S695 phosphorylation via PKA/PKG [27]. Furthermore, it is
not known whether the phospho-T696 antibody recognizes
phospho-T696 in the presence of phospho-S695.Curiously, if
chicken amnion smooth muscle cells are enzymatically isolated
or explanted and placed into culture, there was a marked dif-
ference between intact and passaged cell cultures in Y-27632
mediated reduction of MYPT-1 phosphorylation at both T695
and T850. Y-27632 reduced T695 phosphorylation to
25.3 1.3% of control values in cultured amnion cells, but was
without eﬀect in amnion tissue (93.2 23.7% of control). T850
phosphorylation was reduced to 23.4 4.1% (n ¼ 7) of control
in cultured cells) (Fig. 3D; P < 0:002). These data indicate that
not only is ROK involved in the phosphorylation of MYPT-1Fig. 3. MLCP regulation in chicken amnion. (A) MYPT-1 phosphorylation a
subsequent treatment with Y-27632 (10 lM) in a-toxin permeabilized amnion
but increased at T850 with subsequent inhibition by Y-27632 and 8-Bromo-c
analysis showing no detectable level of CPI-17 expression in chicken gizzard
AM-C) as compared to expression levels in rabbit ileum (R-IL). 20 lg of
phosphorylation in tissue versus cultured cells.at both T695 and T850 in cultured cells, but also that culturing
at early passages causes a fundamental change as compared to
intact tissue where T850 is the signiﬁcant ROK substrate and
which could account for diﬀerences in relevant phosphoryla-
tion sites reported in the literature.
3.5. Recombinant CPI-17 restores agonist-induced sensitization
through generation of GTP RhoA in chicken amnion
Permeabilized ASM showed no contraction when chal-
lenged with a variety of G-protein coupled agonists or PDBu
(Table 1). However, activation of G12=13 family of GPCRs
with the thromboxane A2 analog, U46619, was rescued if
recombinant CPI-17 (10 lM), in the physiological range
found in other smooth muscle [28], was added to tissue strips
of ASM (20.0 4.4% of pCa 6.5 +CPI-17; n ¼ 12) (Fig. 4A
and B) that was sensitive to inhibition by 10 lM Y-27632
(106 18.8% of the Ca2þ sensitization) (Fig. 4C). Re-
combinant CPI-17 alone induced a small component of Ca2þ-
sensitized force as reported previously [29]. It is not clear
whether the recombinant CPI-17 becomes phosphorylated by
a basal kinase activity. The CPI-17-induced rescue of
U46619-induced Ca2þ-sensitized force was accompanied by a
10-fold increase in GTP RhoA (Fig. 4D) when compared
with levels of GTP RhoA in the presence of either U46619,
CPI-17 alone or pCa 6.5, strongly suggesting that CPI-17 has
some previously unrecognized activity upstream of RhoA
leading to its activation. CPI-17-rescued U46619-sensitized
force may reﬂect inhibition of MYPT-1 by the classical CPI-
17 pathway (i.e., through phospho-CPI-17 binding to PP1C),t putative ROK sites following GTPcS-induced Ca2þ-sensitization and
. MYPT-1 phosphorylation is unchanged at two sites (T695 and S849),
GMP (B). Total MYPT-1 was the same in each lane. (C) Western blot
(C-GZ), chicken amnion tissue (C-AM-T) or cultured amnion cells (C-
total protein were loaded per lane. (D) Summary data of MYPT-1
Fig. 4. CPI-17 restores agonist-induced contraction in b-escin permeabilized chicken amnion. (A) U46619, a thromboxane A2 analog, causes no
contraction in intact amnion smooth muscle. (B) Upon addition of CPI-17 (10 lM), U46619 now caused an increase in Ca2þ-sensitization com-
parable to that of GTPcS and AlF4 (Fig. 1). (C) U46619-induced Ca
2þ-sensitization following treatment with CPI-17 could be inhibited by the ROK
inhibitor, Y-27632, bar graph (right). (D) U46619 in the presence of CPI-17 causes an increase in GTP RhoA compared to U46619 or CPI-17 alone.
78 A.S. Stevenson et al. / FEBS Letters 578 (2004) 73–79this would not result in an increase in GTP RhoA but could
contribute to the magnitude of the rescued sensitized force.
U46619 induces large contractions with little change in [Ca2þ]
in mammalian smooth muscle and is thus a potent Ca2þ
sensitizer, largely through activation of the RhoA pathway
[30]. Ca2þ-sensitization with the muscarinic receptor agonist
carbachol was also rescued by addition of CPI-17 with an
amplitude of 29.9 16.7% of pCa 6.5+CPI-17 contraction;
n ¼ 5 (Fig. 4B, bar graph). Stimulation with PDBu (1 lM)
also now caused an increase in contraction and sensitized the
tissue to Ca2þ (20.2 3.7% of pCa 6.5+CPI-17 contraction;
n ¼ 6) (Fig. 4B, bar graph), as described previously [29].
Separate upstream and convergent downstream pathways of
G-protein- and phorbol ester-mediated Ca2þ-sensitization
have been demonstrated in mammalian smooth muscle where
downregulation of PKCs ablated phorbol ester-induced
Ca2þ-sensitization, while retaining normal agonist and
GTPcS responses and vice versa [31,32]. Evidence for sepa-
rate upstream pathways also arises from our previous dem-
onstration that RhoA GDI, which complexes with RhoA,
relaxes agonist and GTPcS-induced Ca2þ-sensitization, but
does not relax force induced by stimulation of PKCs with
phorbol ester [24]. Moreover, GTPcS, which activates the
RhoA/ROK pathway, resulted in a signiﬁcant Ca2þ-sensiti-
zation response in the CPI-17 deﬁcient ASM again pointing
to a role for CPI-17 lying upstream of GTP RhoA. There-
fore, CPI-17 is not critical for GTPcS-induced Ca2þ-sensiti-
zation of ASM. However, the ability of CPI-17 to rescue the
carbachol and U46619-induced Ca2þ-sensitization as well asthe signiﬁcant increase in GTP RhoA suggests that CPI-17
activity is necessary for agonist-induced signaling. These data
strongly support the hypothesis that CPI-17 can rescue the
signaling events upstream of GTP exchange on GDP RhoA,
possibly through the actions of another PP1 family member
targeted by CPI-17 and acting, for example, on RhoGEFs,
RhoGTPase activating proteins (RhoGAPs) or by regulating
the phosphorylation state of GPCRs. This new role for CPI-
17 remains to be explored and its targets identiﬁed.Acknowledgements: This work was supported by a Merck Co. post-
doctoral fellowship (to A.S.S.), a grant from AHA National Center (to
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